丙型肝炎病毒再感染能否被预防?
本文探讨丙型肝炎病毒(HCV)预防性疫苗的开发难点,指出诱导体液和T细胞应答是共识方向,但保护性应答特征尚未明确;基于急性HCV感染自发性清除后仍可再感染但反复清除概率高的观察,防止持续性感染可能比完全灭菌免疫更现实。
要点
- 成功预防性HCV疫苗需同时诱导体液和T细胞应答。
- 疫苗所需保护性T细胞和抗体应答特征尚待完全定义。
- 对多种HCV株的灭菌免疫是否现实仍存疑问。
核心结论
- 开发预防慢性HCV感染的疫苗是全球消除HCV的重要优先事项。
- 基于自发性清除后反复清除概率高的观察,防止HCV持续性感染比实现灭菌免疫更为可行。
主要发现
- 急性HCV感染自发性清除后在高危人群中常发生再感染,但反复清除的概率较高。
- Chumbe等在Gut发表的研究旨在明确原发感染后抗体应答的特定特征是否与真正防止再感染相关。
临床怎么用
- HCV疫苗开发应优先考虑诱导防止持续性感染的免疫应答,而非追求完全灭菌免疫。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Developing a prophylactic vaccine protecting from chronic hepatitis C virus (HCV) infection remains a high priority in efforts to end this worldwide pandemic. 1 There is a broad consensus that a successful prophylactic vaccine should induce both humoral and T-cell responses for the highest efficacy in preventing chronic infection. 2 However, detailed characteristics of T-cell and antibody responses that a vaccine must elicit for effective protection await full definition. It also remains open whether sterilising immunity against different HCV strains is a realistic goal. Protection from persistence appears more feasible, based on observations that, although spontaneous clearance of acute HCV infection is often followed by reinfections in high-risk populations, the likelihood of repeated HCV clearance is high. 3 In Gut , 4 Chumbe aimed to define whether specific characteristics of the antibody response after a primary infection relate to real protection from reinfection. For this, they...
引用
- Gut (BMJ):Catch me if you can! Is there protection from HCV (re)infection?
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。